Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options. Review uri icon

Overview

abstract

  • Successful treatment of obesity requires a multidisciplinary approach including dietary strategy, physical activity, and behavioral modification. The seven FDA-approved anti-obesity medications are phentermine, orlistat, phentermine/topiramate ER, naltrexone SR/bupropion SR, liraglutide 3.0 mg, semaglutide 2.4 mg, and tirzepatide. Obesity is a chronic disease and these medications should be prescribed with the intention of long-term use. In this article, we summarize data from phase 3 clinical trials which led to drug approval, and we review the clinical indications, mechanism of action, dosing/administration, side effects, drug interactions and contraindications for each medication.

publication date

  • March 1, 2025

Research

keywords

  • Anti-Obesity Agents
  • Obesity

Identity

Scopus Document Identifier

  • 85216840043

Digital Object Identifier (DOI)

  • 10.1016/j.ecl.2024.09.003

PubMed ID

  • 39919879

Additional Document Info

volume

  • 54

issue

  • 1